Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
HIV, HCV and TB Pipeline Report

Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

Published
21 July 2014
From
Treatment Action Group & i-Base
AbbVie 3D regimen cures most genotype 1 HCV in people with HIV and HCV co-infection

An oral regimen of three direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people with both HIV and

Published
21 July 2014
By
Liz Highleyman
Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic

Published
21 July 2014
By
Liz Highleyman
J&J beats forecasts, helped by new hepatitis C drug

Johnson & Johnson (JNJ.N) reported sharply better-than-expected quarterly revenue and earnings, fueled by strong sales of newer prescription drugs, including its Olysio treatment for hepatitis C.

Published
16 July 2014
From
Reuters
US govt demands more pricing info on Gilead HCV pill

The cost of Gilead Sciences’ hepatitis C pill Sovaldi is once again under the spotlight with the US Senate Finance Committee requesting detailed pricing information.

Published
15 July 2014
From
Pharma Times
EU nations join forces against 'exorbitant' hepatitis C drug: France

France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Published
10 July 2014
From
Medical Xpress
US: Studies look at hepatitis C care cascade and healthcare utilization

Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE.

Published
08 July 2014
From
HIVandHepatitis.com
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor.

Published
08 July 2014
From
Bristol-Myers Squibb press release
Fighting for their lives: Economist Intelligence Unit report finds patient groups lead global efforts to address hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide.

Published
25 June 2014
From
Janssen press release
2014 UK Consensus Guidelines — Hepatitis C Management and Direct-acting Anti-viral Therapy

These expert guidelines are sponsored by the Scottish government and take representative opinion from the British Society of Gastroenterology Liver Committee, British Association for the Study of Liver, the Scottish Society of Gastroenterology, the Scottish Viral Hepatitis group, the Scottish Viral Hepatitis Nurses group and the British Viral Hepatitis group.

Published
19 June 2014
From
Medscape (requires registration)
← First12345...40Next →

Filter by country